RNA250117C29000
- 0.85
- 0.000.00%
Avidity Biosciences Newsroom
RBC Capital Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $67
Express News | Avidity Biosciences Inc : Leerink Partners Cuts Target Price to $60 From $64
Avidity Biosciences, Inc. (RNA): The Biotech Stock With Biggest Upside Potential
BofA Securities Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $51
Bank of America Securities Remains a Buy on Avidity Biosciences (RNA)
Barclays Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $63
Analysts Offer Insights on Healthcare Companies: Avidity Biosciences (RNA), Celldex (CLDX) and Centessa Pharmaceuticals (CNTA)
H.C. Wainwright Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $72
Wells Fargo Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $75
Analysts Offer Insights on Healthcare Companies: NeuroPace (NPCE), Tecan Group AG (OtherTCHBF) and Avidity Biosciences (RNA)
Avidity Biosciences Plans to Submit First Biologics License Application This Year
Express News | Avidity Biosciences: Accelerated Approval Path Confirmed for Del-Zota; Bla Submission Planned for Year End 2025
Press Release: Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
Companies Like Avidity Biosciences (NASDAQ:RNA) Are In A Position To Invest In Growth
Express News | Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
H.C. Wainwright Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $72
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Avidity Biosciences Price Target Announced at $72.00/Share by HC Wainwright & Co.